Dose-response Study of OPC-12759 Ophthalmic Suspension

Trial Profile

Dose-response Study of OPC-12759 Ophthalmic Suspension

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2018

At a glance

  • Drugs Rebamipide (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 06 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top